EC Number   |
Inhibitors |
Structure  |
|---|
   3.5.1.89 | more |
not inhibitory up to 0.1 mM: 2-deoxy-2-ureido-D-glucosyl-beta1-6-D-myo-inositol-1-phosphoryl-sn-1,2-dipalmitoylglycerol, 2-deoxy-2-ureido-D-glucosylalpha1-6-D-(2-O-octyl)myo-inositol-1-phosphoryl-sn-1,2-dipalmitoylglycerol |
 |
| 3.5.1.89 | more |
treatment with EDTA consistently causes up to 2% reduction in activity, the activity is not significantly affected by treatment with 1,10-phenanthroline |
|
| 3.5.1.89 | more |
inhibitor identification via zinc binding fragment screening, structure activity relationship, hydroxamic acid and 2-OH are essential for potency, substitution is tolerated at the 4- and 5-positions. No inhibition by 2-bromo-N-hydroxybenzamide and 2-amino-N-hydroxybenzamide |
|
| 3.5.1.89 | more |
(1R,2R)-1-O-(2-acetylamino-2-deoxy-beta-D-glucopyranosyl)-cyclohexanediol 2-(1,2-di-O-hexadecanoyl-sn-glycerol 3-phosphate) is neither a substrate nor an inhibitor |
|
| 3.5.1.89 | more |
inhibitor search by structural based virtual screening (SBVS), molecular modeling, and docking study, overview |
|
| 3.5.1.89 | EDTA |
complete inhibition at 10 mM, the enzyme irreversibly loses activity upon incubation with a metal chelator |
  |
| 3.5.1.89 | 2-hydroxybenzoic acid |
97% inhibition at 1 mM |
|
| 3.5.1.89 | ethambutol |
docking study, the effective enzyme inhibitor may be useful in the treatment of African sleeping sickness |
|
| 3.5.1.89 | phenyl 2-(carboxymethyl)-2-deoxy-1-thio-alpha-D-glucopyranoside |
- |
|
| 3.5.1.89 | salicylic hydroxamic acid |
enzyme inhibitor with high ligand efficiency, proposed mode of action, overview |
|
